VC firms in £85m series-B for Orchard Therapeutics

Other new investors included Temasek, Cowen Healthcare Investments, Juda Capital, Pavilion Capital, RTW Investments, Agent Capital and 4Bio Capital. Existing investors F-Prime Capital Partners and the UCL Technology Fund also took part.

Simone Song, a senior partner at ORI Capital, will join Orchard's board of directors as part of the deal.

The fresh capital will be used for the global launch of the company's lead gene therapy product, OTL-101. It has been developed to treat a rare inherited immune system disorder and has been granted breakthrough therapy designation by the FDA.

Orchard will also expand its manufacturing infrastructure and business development activity.

Previous funding
F-Prime led a £21m series-A for Orchard in May 2016, and later in the year the company received a $20m grant from the California Institute of Regenerative Medicine.

Company
Orchard is a privately held clinical-stage biotechnology company based in the UK and in California. Orchard develops gene therapies for rare disorders. The company works in partnership with gene-therapy centres including University College London, Great Ormond Street Hospital, the University of Manchester, Central Manchester University Hospital, the University of California and Boston Children's Hospital.

People
ORI Capital – Simone Song (senior partner).
Orchard Therapeutics – Mark Rothera (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• UK / Ireland
• Venture